

REMARKS

Claims 9-20 are pending. Claims 15-20 are withdrawn from consideration as the result of restriction. Claims 9-14 are currently under consideration.

A. Restriction Requirement

The Office Action required restriction under 35 U.S.C. 121 and 372. Specifically, Applicants are required to elect a single invention from Groups I-II:

Group I: Claims 9-14, drawn to a method of treating an angiogenesis-mediated ocular disorder in subject in need of such treatment which comprises administering to the subject an effective amount of a compound of formula (I).

Group II: Claims 15-20, drawn to a package comprising a compound of formula (I), and instruction for use in treating an angiogenesis-mediated ocular disorder.


Applicants hereby elect Group I, without traverse.

B. Election of Species

The Office Action also required Applicants to elect a single specific angiogenesis-mediated ocular disorder. Applicants hereby elect "age-related macular degeneration" as the specific species. The claims that encompassing the elected species/invention are claims 9-14.

In view of the above, Applicants submit that the application is now in condition for allowance and early notification of allowance is earnestly sought. If any issues remain, the Examiner is invited to telephone the undersigned.

Respectfully submitted,


Jennifer C. Chapman
Attorney for Applicants
Reg. No. 47,487

Novartis
Patents Pharma
One Health Plaza, Building 104
East Hanover, NJ 07936-1080
(862) 778-1202

Date: *July 16, 2008*